Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | PHA-665752 + Xentuzumab |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| PHA-665752 | PHA665752|PHA 665752 | MET Inhibitor 59 | PHA-665752 is a small molecule inhibitor of MET, which inhibits MET kinase activity and downstream signaling, potentially resulting in increased apoptosis and decreased proliferation and migration of tumor cells (PMID: 14612533, PMID: 29456739). | |
| Xentuzumab | BI 836845 | IGF1/2 Antibody 2 | Xentuzumab (BI 836845) is a monoclonal antibody that binds to IGF-1 and IGF-2 and prevents binding to the IGF receptor (IGF-1R), resulting in decreased IGF-1R signaling (PMID: 32161368, PMID: 32054790). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|